Semaglutide: research overview

The short version

Semaglutide is a long-acting analogue of the natural hormone GLP-1 (glucagon-like peptide-1). It is FDA-approved for type 2 diabetes, chronic weight management, reduction of cardiovascular events in adults with obesity and established heart disease, and — since 2025 — metabolic dysfunction-associated steatohepatitis (MASH). It works by mimicking GLP-1: it stimulates insulin release from the pancreas in a glucose-dependent way, suppresses inappropriate glucagon release, slows gastric emptying, and — most importantly for weight — activates appetite-regulating circuits in the hypothalamus and brainstem to reduce food intake.

The defining feature of semaglutide compared with the other peptides on this desk is its evidence base: there are large, independent, replicated phase 3 randomized controlled trials across multiple disease categories with tens of thousands of participants ^[15][16][14]. The trial data are public, peer-reviewed, and robust. It is not a research compound in the same sense as BPC-157 or Ipamorelin.

This page summarizes published research and approved-label information. It does not recommend doses for individual people and is not medical advice.

Note: the brand names for semaglutide products are not used on this desk. All discussion uses the generic compound name only.

What it is

Semaglutide is a 31-amino-acid acylated analogue of human GLP-1, sharing approximately 94% sequence identity with the natural hormone. Two structural changes compared with native GLP-1 give it durability:

1. Position 8 substitution. The alanine at position 8 is replaced with alpha-aminoisobutyric acid (Aib), which blocks the enzyme DPP-4 from cleaving the peptide. Native GLP-1 is destroyed by DPP-4 within about 2 minutes; semaglutide is not.
2. Albumin-binding fatty acid side chain. A C18 di-acid fatty chain is attached at the lysine at position 26, via a linker. This lipid anchor binds tightly and reversibly to serum albumin, protecting the peptide from kidney filtration and metabolic breakdown. The result is a circulating half-life of approximately one week, compared to minutes for native GLP-1.

It is available as a once-weekly subcutaneous injection and a once-daily oral tablet (which uses the absorption enhancer SNAC to achieve roughly 0.4–1% oral bioavailability; administration errors with the oral form can substantially reduce the absorbed dose).

Synonyms in the literature include NNC0113-0217, NN9535, and OG217SC.

How it works

Semaglutide activates the GLP-1 receptor (GLP-1R), which is expressed in multiple tissues:

• Pancreatic beta cells — GLP-1R stimulation potentiates glucose-dependent insulin secretion. 'Glucose-dependent' is important: the effect is strongest when blood glucose is high and wanes as glucose normalizes, which limits hypoglycemia risk compared with some other diabetes drugs.
• Pancreatic alpha cells — GLP-1R activation suppresses glucagon release when blood sugar is already adequate, reducing inappropriate glucose production by the liver.
• Gastric smooth muscle / vagal afferents — semaglutide slows gastric emptying, contributing to its glycemic effects and, in part, to its gastrointestinal side-effect profile.
• Hypothalamus and brainstem — semaglutide reaches appetite-regulating centers, particularly the arcuate nucleus and area postrema. It activates anorexigenic (appetite-suppressing) neurons and inhibits orexigenic (hunger-promoting) neurons, reducing food intake and changing food preferences. This is considered the primary mechanism of its weight-lowering effect.
• Cardiovascular and renal tissues — GLP-1 receptors are expressed in the heart, blood vessels, and kidneys, and some of semaglutide's cardiovascular and renal protective effects appear to operate through these receptors independently of blood sugar.

What the research shows

STEP 1 — Weight management (2021). Wilding et al. ^[16] randomized 1,961 adults with overweight or obesity (without diabetes) to once-weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks. Mean body-weight change: −14.9% with semaglutide versus −2.4% with placebo — a treatment difference of approximately 12.4 percentage points, statistically significant. This is the pivotal trial that supported regulatory approval for chronic weight management.

SELECT — Cardiovascular outcomes (2023). Lincoff et al. ^[15] randomized 17,604 adults with obesity or overweight and preexisting cardiovascular disease (but no diabetes) to semaglutide 2.4 mg or placebo. Primary composite: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Hazard ratio 0.80 (95% CI 0.72–0.90; P<0.001) — a 20% relative reduction in major cardiovascular events. This trial established that semaglutide reduces heart-attack and stroke risk in people with obesity and heart disease independent of glucose control.

FLOW — Kidney outcomes (2024). Perkovic et al. ^[14] randomized 3,533 adults with type 2 diabetes and chronic kidney disease to once-weekly semaglutide 1.0 mg or placebo. Primary composite: kidney failure, ≥50% eGFR decline, or kidney/cardiovascular death. Hazard ratio 0.76 (95% CI 0.66–0.88) — a 24% relative risk reduction. This trial extended semaglutide's evidence base to kidney disease progression.

SURMOUNT-5 — Comparative efficacy (2025). Aronne et al. ^[13] conducted the first head-to-head trial (n=751) comparing semaglutide 2.4 mg to tirzepatide (a GIP+GLP-1 dual agonist) in adults with obesity. At 72 weeks: −13.7% for semaglutide versus −20.2% for tirzepatide (P<0.001). Semaglutide produced meaningful weight loss; tirzepatide produced more. Both worked.

Safety review (2021). Smits and Van Raalte ^[17] reviewed semaglutide's safety across clinical trials and pharmacovigilance. Summary: a favorable overall risk–benefit profile, predominantly mild-to-moderate gastrointestinal effects (nausea in roughly one-third of patients), an increased risk of gallbladder disease, and pancreatic/thyroid-cancer signals whose definitive conclusions could not yet be drawn given low incidence.

Reported effects, cautions and safety

What people commonly report (anecdotal, not clinical evidence)

The following comes from patient review platforms and pharmacovigilance-level qualitative data. It supplements the trial data, which are the primary record.

• Appetite suppression / quieter 'food noise' — by far the most common benefit people describe. Constant background thinking about food goes quiet, often within the first week or two. Many call this life-changing. Anecdotal.
• Reduced sugar and food cravings — people repeatedly report that sweet-tooth cravings drop sharply and that fried or greasy foods become less appealing. Anecdotal.
• Reduced desire to drink alcohol — an unexpected secondary finding in many accounts. Some people describe losing interest in drinking alongside food cravings. Anecdotal.
• Nausea (sometimes with vomiting) — the single most reported side effect, mentioned by roughly a third of reviewers. It peaks in the first weeks and after each dose increase, and it worsens markedly after overeating or eating fatty foods. Clinical trial data confirm nausea is the most common treatment-emergent adverse event ^[17].
• Sulfur / 'egg' burps — a distinctive complaint, frequently described as embarrassing and more common than official lists suggest. Often accompanied by bloating and a sense of food sitting too long in the stomach. Anecdotal.
• Bowel changes (constipation and diarrhea) — people report both extremes, sometimes alternating. Confirmed in clinical trial adverse-event data. Anecdotal and clinical.
• Fatigue and tiredness, especially after injection — commonly reported in the early weeks. Usually described as easing with adjustment. Anecdotal.
• Hair shedding — reported by a smaller group, typically attributed to the rate and magnitude of weight loss (telogen effluvium) rather than to the drug itself. Supported by pharmacovigilance-signal data.

Cautions grounded in the literature

• Gastrointestinal intolerance. Nausea, vomiting, diarrhea, and constipation are the dominant adverse effects and the leading cause of discontinuation. Predominantly mild-to-moderate and transient, concentrated in the titration period ^[17].
• Thyroid warning. A personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication. No clear human MTC signal has been established, but the boxed warning derives from rodent carcinogenicity findings at supratherapeutic exposures ^[17].
• Acute pancreatitis. A class warning for GLP-1 receptor agonists. Meta-analyses have not confirmed a statistically significant increase in pancreatic cancer, but treatment is discontinued if pancreatitis is suspected ^[17].
• Gallbladder disease. An increased risk of cholelithiasis (gallstones) is a confirmed finding, attributed largely to the rate and magnitude of weight loss ^[17].
• Diabetic retinopathy with rapid glucose correction. In SUSTAIN-6, retinopathy complications were significantly more frequent in semaglutide-treated patients with pre-existing retinopathy undergoing rapid HbA1c lowering. The likely mechanism is early worsening from rapid glycemic correction, not direct drug toxicity. Monitoring is advised.
• Lean-mass loss. Body-composition substudies show a meaningful fraction of total weight lost is lean (muscle) mass, raising sarcopenia concerns, especially in older adults.
• Weight regain after stopping. STEP 1 extension data showed a mean weight regain of approximately 11.6 percentage points within one year of stopping semaglutide. This frames it as a chronic intervention, not a short course.
• Pregnancy contraindication. Semaglutide is contraindicated in pregnancy. Because its half-life is about one week, effectively complete clearance takes roughly five weeks, and guidance advises discontinuing well before planned conception.

Where it fits in the research-fundamentals map

Semaglutide is the most clinically established compound on this desk by a significant margin. It sits at the metabolic and GLP-1 axis corner of the research-fundamentals map — the only member with large, independently replicated phase 3 trials and a regulatory track record across multiple indications. Reading it alongside the unapproved research compounds on this desk makes the contrast in evidence levels very clear: what 'proven in large human trials' actually looks like versus what 'mostly preclinical, thin human data' looks like. Compare all four compounds.